Founded in 2007 and headquartered in the global innovation hub of Tel Aviv-Yafo, Israel, PRF Technologies Ltd. is a leading specialty pharmaceutical company dedicated to the reformulation of established therapeutics. Formerly known as PainReform Ltd., the company underwent a comprehensive rebranding in January 2026 to align its corporate identity with its expanding technological capabilities and diversified product pipeline. The core mission of PRF Technologies is to enhance the clinical profile of proven drugs through advanced delivery systems, thereby reducing development risks while significantly improving patient outcomes in surgical and post-operative settings. By focusing on established molecules, the company bridges the gap between traditional pharmacology and cutting-edge medical engineering.
The company’s primary product lines, OcuRing-K and PRF-110, represent significant leaps in drug delivery technology. OcuRing-K is a bio-erodible, sustained-release implant specifically designed to be applied to the haptic of an intraocular lens during cataract surgery, ensuring consistent medication delivery without the need for frequent patient intervention. Complementing this is PRF-110, a proprietary, viscous, oil-based solution engineered for direct instillation into surgical wounds. PRF-110 provides localized and extended post-operative analgesia, addressing the critical need for effective pain management while minimizing the systemic side effects and dependency risks associated with traditional oral or intravenous painkillers.
PRF Technologies occupies a strategic position within the multi-billion dollar global markets for ophthalmology and surgical pain management. As the global geriatric population grows, the frequency of cataract surgeries continues to rise, positioning OcuRing-K as a vital tool for surgeons worldwide. Simultaneously, the global medical community's urgent shift toward non-opioid pain management solutions provides a robust tailwind for the adoption of PRF-110. The company targets high-volume surgical centers, specialized ophthalmic clinics, and large-scale hospital networks, leveraging its Israeli-based R&D excellence to meet the rigorous regulatory standards of the FDA and EMA, ensuring a broad international reach.
Looking toward the future, PRF Technologies is executing a strategic pivot to expand its proprietary delivery platforms into new therapeutic categories. Following its 2026 rebranding, the company is focused on accelerating its clinical trial pipeline and fostering high-value global partnerships with major pharmaceutical players. The strategic direction involves not only the commercialization of its current assets but also the exploration of next-generation biodegradable delivery systems for a wider array of active pharmaceutical ingredients. With a commitment to sustainable growth and continuous innovation, PRF Technologies is poised to remain at the forefront of the specialty pharmaceutical industry, delivering long-term value to patients, providers, and shareholders.
Economic Moat
The company's moat is built upon its proprietary oil-based delivery platform and a robust portfolio of patents covering bio-erodible surgical implants. This unique technological synergy allows for the precise, extended release of therapeutics, creating high barriers to entry and significant clinical differentiation from generic alternatives.